Vanda Pharmaceuticals Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $216.1M | $198.8M | $192.6M | $254.4M | $268.7M |
| Selling, general & administrative | $238.0M | $146.4M | $112.9M | $136.5M | $124.0M |
| Research and development | $109.3M | $74.4M | $76.8M | $85.8M | $75.4M |
| Operating income | -$151.2M | -$40.7M | -$14.0M | $6.3M | $42.2M |
| Pretax income | -$138.6M | -$22.9M | $6.3M | $11.3M | $42.4M |
| Income tax expense | $81.8M | -$4.0M | $3.8M | $5.0M | $9.2M |
| Net income | -$220.5M | -$18.9M | $2.5M | $6.3M | $33.2M |
| Balance Sheet | |||||
| Cash and equivalents | $84.9M | $102.3M | $135.8M | $135.0M | $52.1M |
| Current assets | $347.3M | $438.9M | $432.9M | $519.3M | $478.3M |
| Total assets | $488.9M | $656.2M | $648.4M | $634.2M | $593.8M |
| Current liabilities | $145.2M | $100.0M | $87.7M | $91.4M | $74.4M |
| Total liabilities | $161.8M | $117.7M | $103.5M | $107.0M | $88.9M |
| Stockholders' equity | $327.2M | $538.5M | $544.9M | $527.2M | $504.9M |
| Cash Flow Statement | |||||
| Cash from operations | -$109.4M | -$15.8M | $12.8M | $32.0M | $64.2M |
| Depreciation and amortization | $1.1M | $859,000 | $920,000 | $1.2M | $1.4M |
| Stock-based compensation | $9.5M | $12.4M | $14.0M | $16.3M | $15.4M |
| Capital expenditure | $998,000 | $490,000 | $383,000 | $679,000 | $552,000 |
| Free cash flow | -$110.4M | -$16.2M | $12.4M | $31.3M | $63.7M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 60.1M · Free float 78.7%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.